They also confirmed that the systemic administration of DCs that pulse ALPs and ovalbumin peptides strongly increased CTL activity, the generation of CD107a-positive T cells, and Th1-mediated humoral immunity, with a significant reduction in the tumor growth of murine thymoma. The gene discussed is LAMP1; the disease is thymoma.